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& therapy, and studies of the determinants of CMV-speciﬁc
immune recovery, are a priority for this patient population.
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Allogeneic hematopoietic stem cell transplant (HCT) is
a curative therapy for sickle cell disease (SCD). However,
majority of patients lack a matched sibling or unrelated
donor. The use of a partially matched related donor would
provide donors for majority of the patients. We report the
results of 8 consecutive pediatric patients with SCD who had
a prior stroke, who underwent a T cell depleted HLA-hap-
loidentical HCT using a reduced intensity conditioning
regimen without total body irradiaiton. The median age was
75 yrs (4-17) with the median follow up of 73 yrs (3-9).
The ﬁrst 3 patients received ﬂudarabine (150-200 mg/m2),
thiotepa (10mg/kg), targeted busulfan (900 ng/ml for 4 d),
rabbit antithymocyte globulin (rATG) (10mg/kg x 3 d), and
OKT3 (0.1mg/kgmaximum over d +1 to +20). The subsequent
5 patients received busulfan (900ng/ml x 4 d), thiotepa
(10mg/kg), cyclophosphamide (200 mg/kg) and OKT3
(0.1mg/kg max on d-10 to +17) as well as mycophenolate
mofetil for graft versus host (GVHD) prophylaxis. The
product consisted of a CD34+ selected product infused on d0
and a CD3+ depleted product infused on d+1. The infused
products had a mean total nucleated cell (TNC) of 450680 x
106 kg (10-1890), CD34+ cells of 25.416.3 x 106/kg (6-57)
and CD3+ cells of 0.070.07 x 106/kg (0.006-0.168). All 8
patients achieved donor engraftment with a median of 12
d (10-14). Donor engraftment was maintained in 5 patients,
with one patient requiring a second stem cell infusion. TheTable 1
Patients and donors characteristics
Patient
number
Age
(years)
Sex Donor
Age
(years)
Donor
Sex
Source of
Progenitor
Age
Dif
(ye
1 6 Male 62 Male PB 56
2 5 Male 60 Female PB 55
3 2.5 Female 45 Female BM 42.
4 5.5 Female 63 Male PB 57.
5 7 Male 75 Female PB 68
6 2 Female 60 Female PB 58
7 11 Male 69 Male PB 58
8 8.5 Female 68 Male PB 59.
9 9.5 Female 46 Female BM 36.
10 2 Male 48 Female BM 46
11 1 Male 74 Male PB 73
12 9 Male 62 Male PB 53
13 0.25 Female 71 Male PB 70.
PB: Peripheral Blood, BM: BoneMarrow, ALL: Acute Lymphoblastic Leukemia, TM: T
CD4 dif: CD4 deﬁciency, AML: Acute Myeloid Leukemia, MPS: Mucopolysaccharidomedian time to rejection for the 4 patients was 30 d (22-44)
after HSCT. Of the 5 engrafted patients, 4 patients developed
acute GVHD (3 with grade I-II and 1 with Grade III). Of the 5
engrafted patients, 3 developed chronic GVHD (1 with
limited and 2 with extensive). The 2 patients with extensive
GVHD died of complication of GVHD. The 3 surviving
patients have been transfusion independent with no
evidence of SCD related complications. Indices of hemolysis
decreased after HCT with decreased reticulocyte count, bili-
rubin and LDH. Themedian hemoglobin increased from9.6
0.6 to 13.6  2. Renal and cardiac were stable after HCT. MRI
showed no new infarct or vessel occlusion. In summary, 3
patients survived free of SCD, 2 engrafted but died of
complications from GVHD and 3 had recurrent SCD after
graft rejection. Despite good outcomes in 3 of the 8 patients,
rejection, chronic GVHD and transplant related mortality
were signiﬁcant problems. Recently, Bolaños-Meade et al.
published the result of haploidentical HCT for SCD using
post-transplant cyclophosphamide. Both regimens encoun-
tered graft failure, however GVHD and mortality was not as
prevalent as our report. Though limited, our data suggest
that for patients with SCD, graft-versus-host disease
prophylaxis after haploidentical HCT with high dose cyclo-
phosphamide may be a safer regimen and further studies are
warranted.
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Background: HLA matching is one of the most important
factors affecting patients' prognosis after hematopoietic
stem cell transplantation (HSCT). Currently when there are
no HLA-match siblings, transplantation centers try to ﬁnd
unrelated HLA-matched donor through bone marrow and
cord blood registries. However, few studies showed that
searching extended families such as parents, grandparents,
aunts and uncles for an appropriate donor is useful.
Methods: This is a retrospective study from our center in
which the patients who underwent HSCT of any diseases
and their grandparents were as donors included in the
study. The principal data including graft-versus-host-diseaseference
ars)
Disease Acute
GVHD
Chronic
GVHD
Patient Status
ALL Yes No Full chimerism/Alive
TM II Yes No Full chimerism/Alive
5 LAD I Yes Yes Full chimerism/Alive
5 FA Yes No Full chimerism/Alive
TM II Yes No Rejected/Dead
AML No No Rejected/Alive
FA No No Full chimerism/Alive
5 CD4 dif. Yes Yes Full chimerism/Alive
5 AML Yes No Rejected/Dead
MPS I Yes No Full chimerism/Alive
LAD I Yes Yes Full chimerism/Alive
TM III No No Rejected/Alive
75 SCID Yes No Full chimerism/Alive
halassemia Major, LAD: Leukocyte Adhesion Deﬁciency, FA: Fanconi Anemia,
ses, SCID: Severe Combined Immunodeﬁciency.
